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The International Society for Stem Cell Research 11
th Annual Meeting was held in Boston in June 2013, bringing together just over
4000 attendees. An emphasis on therapeutic applications in many talks reﬂected the maturation of the stem cell ﬁeld from its origins
in basic science to one that is beginning to show therapeutic promise.
This year’s International Society for Stem Cell Research
(ISSCR) Annual Meeting returned to Boston, where the
organization was founded 11 years ago. Remarkably, the
number of ISSCR members has grown 20-fold, from 200
to 4000, over the years, reﬂecting the increasing interest
in stem cell research. The fact that this report appears in
the ISSCR’s new journal provides further documentation
of the expansion of the stem cell ﬁeld and, with it, the
growthofthesociety.Justover4000attendeesfromaround
the world gathered in Boston to celebrate the ISSCR’s
anniversary and to share their exciting results with the
scientiﬁc community. This year, particular emphasis was
given to presentations discussing therapeutic applications,
exemplifying the maturation of the stem cell ﬁeld from its
origins in basic science to one that is beginning to show
therapeutic promise.
Pluripotency and Epigenetic Gene Regulation
James Thomson (Morgridge Institute for Research, USA)
received this year’s McEwen Award for Innovation for his
seminal contributions to human pluripotent stem cell
research. The award was introduced by Shinya Yamanaka,
ISSCR President (2012–2013) and presented by Cheryl
and Rob McEwen, the founding contributors of this
prestigious ISSCR award (Figure 1). Thomson shared his
personal perspective on the derivation of the ﬁrst human
embryonic stem cell (ESC) lines in 1998 with a discussion
of the scientiﬁc, legal, and political challenges the ﬁeld of
human pluripotent stem cell research was facing until the
derivation of the ﬁrst human induced pluripotent stem
cells (iPSCs) in 2007 by Yamanaka’s and his laboratories.
Edith Heard (INSERM, Institut Curie, France) discussed
recent data from her laboratory interrogating an unex-
pected link between X chromosome inactivation and early
development. Female mouse ESC lines carry two active X
chromosomes. By comparing female and male ESC lines,
Heard noticed that pluripotency-related genes (e.g., Nanog,
Esrrb) are expressed more abundantly in female than in
male ESCs. Moreover, female ESCs exhibited a delay in
exiting pluripotency compared to male ESCs when stimu-
lated with FGF and ACTIVIN A. Mechanistically, Heard’s
lab could show that female ESCs inhibited the differentia-
tion-promoting mitogen-activated protein kinase (MAPK)
signaling pathway more efﬁciently than male ESCs. This,
in turn, led to a reduction in the expression of the de
novo methyltransferases DNMT3A/B and thus inefﬁcient
methylation silencing of pluripotency genes. While the
X-linked gene(s) responsible for decreased MAPK signaling
and global hypomethylation remain elusive, this study
provided a compelling mechanism by which X chromo-
some inactivation is tightly linked with developmental
progression.
Richard Young (Whitehead Institute, USA) summarized
work from his laboratory, which identiﬁed enhancer ele-
ments that are densely occupied by Mediator coactivator
and cell type-speciﬁc master transcription factors (Whyte
et al., 2013). These so-called ‘‘super enhancers’’ are tran-
scriptionally more active and more sensitive to perturba-
tion than regular enhancers. They are typically found
around loci that specify cell identity, e.g., Esrrb and Klf4
in ESCs or MyoD in muscle cells. Of note is Young’s labora-
tory’sﬁndingthatcancercellsoftenutilizesuperenhancers
to corruptcell identity. Anexample isthe immunoglobulin
enhancer that is fused to the MYC gene in multiple
myeloma. Given that the transcriptional cofactor BET-
bromodomain (BRD)-4 is also enriched at super-enhancers,
treatment of myeloma cells with the BRD inhibitor, JQ1,
resulted in selective decommissioning of this and other
oncogenic enhancers. These ﬁndings provide an exciting
possible strategy to target oncogenes without perturbing
normal cellular function (Love ´n et al., 2013).
Timm Schroeder (Swiss Federal Institute of Technology,
Switzerland) presented his laboratory’s approach to study-
ing pluripotent and multipotent stem cell decisions by
utilizing long-term single cell imaging strategies. Dubbed
‘‘TTT’’ for ‘‘Timm’s Tracking Tool,’’ Schroeder has generated
imaging and software capabilities to track individual stem
and progenitor cells carrying ﬂuorescent reporter alleles
that indicatedistinct lineagedecisions. Heusedthis system
to revisit the old dogma that hematopoietic progenitors
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karyocyte/erythroid (MegE) lineages by coexpressing
specifying transcription factors of both lineages (e.g.,
PU.1 for GM lineage and GATA-1 for MegE lineage) until
one factor ‘‘wins,’’ shifting the balance toward one lineage
in a stochastic manner. In contrast to this model,
Schroeder’s laboratory found that very few progenitors
ever coexpress both lineage markers but instead directly
upregulate either PU.1 during GM differentiation or
GATA-1 during MegE differentiation. His laboratory also
exempliﬁed the use of single cell imaging with reporters
to study monoallelic versus biallelic expression of pluripo-
tency genes. For example, Schroeder could show by
tracking ESCs expressing two different colors from each
of the endogenous Nanog loci that NANOG is, in fact,
primarily expressed from both alleles at a given time
(Filipczyk et al., 2013).
Ian Chambers (University of Edinburgh, UK) summa-
rized recent work from his laboratory on the role of
OCT4 expression levels on the heterogeneity of ESCs.
His laboratory made the surprising observation that
Oct4 heterozygous mutant ESCs are more refractory to
differentiation cues and exhibit more homogenous
NANOG expression compared to wild-type cells (Kar-
wacki-Neisius et al., 2013). This heterogeneity was linked
to refractoriness to FGF signaling, which normally stimu-
lates differentiation, as well as hyper-responsiveness to
LIF and increased expression of Wnt ligands. Despite
a lower level of expression, in Oct4 +/  cells, OCT4
protein showed higher occupancy at the chromatin of
targets that reinforce pluripotency, such as Esrrb and
Wnt6, providing a possible explanation for the observed
phenotype.
Josef Penninger (Institute of Molecular Biotechnology,
Austria) demonstrated the usefulness of haploid mouse
ESC lines to perform saturated genetic screens at low cost
and with high efﬁciency. By using loxP-ﬂanked viral vec-
tors, his laboratory can screen 50–100 million mutations
in one experiment. Cre-mediated removal of the gene
trap virus allows testing for speciﬁcity of the obtained
phenotype. Using several examples, Penninger presented
thesuccessfulidentiﬁcation of moleculeswhose disruption
conferred resistance to ricin-induced cell death and might
thus provide potential ‘‘antidotes.’’ Moreover, he showed
that Notch1 expression is essential for blood vessel sprout-
ing from embryoid bodies derived from haploid ESCs,
exemplifying the utility of this approach to study mecha-
nisms of cellular differentiation. His institute in Vienna
is now gearing up to generate a library of haploid ESC
cloned carrying mutations in essentially all genes for
academic distribution.
Coaxing Pluripotent Cells into Mature Cells
Several plenary talks discussed efforts to drive differentia-
tion of pluripotent cells toward therapeutically relevant,
mature cell types. For example, Douglas Melton (Harvard
University, USA) gave an update on his laboratory’s
approach to coax human ESCs and iPSCs into insulin-
producing cells by recapitulating normal stages of develop-
ment. This strategy allowed his lab to generate populations
of insulin-producing cells within only 3 weeks. However,
a major challenge is that these in vitro-derived cells are
not mature, glucose-sensing b cells. His laboratory is
takingthreeapproachestosolvethisproblem:(1)coculture
of differentiating cells with endothelial cells, which are
important for b cell maturation in vivo—this strategy
Figure 1. McEwen Award for Innovation
Winner James Thomson (second from right)
with Shinya Yamanaka, ISSCR President
(2012-2013) (left), and Cheryl and Rob
McEwen.
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scriptional comparison of in vitro-derived and in vivo-
matured b cells to identify candidate genes that promote
maturation; and (3) combinatorial chemical screening for
compounds that enhance glucose-dependent insulin
secretion. Melton presented a combination of four com-
poundsthatsigniﬁcantlyenhancedglucoseresponsiveness
of in vitro-derived b cells upon transplantation into SCID
mice.
Kenneth Zaret’s (University of Pennsylvania, USA)
approach to this question is to study the dynamic changes
of epigenetic modiﬁcations during the embryonic develop-
ment of b cells, with the goal to identify responsible
enzymes and then small molecules that could promote
b cell formation for stem cell differentiation studies. His
laboratory identiﬁed repressive H3K27 methylation
domains in undifferentiated b cell progenitors that map
over b cell genes. Accordingly, his group showed that ge-
netic loss of the catalyzing enzyme EZH2 in the developing
pancreas or adding chemical inhibitors of EZH2 to early
pancreatic explants resulted in an increased number of b
cell progenitors in vivo and in vitro, respectively.
Zaret also discussed his recent work on the immediate
response of somatic cells to reprogramming factor expres-
sion (Souﬁ et al., 2012). This study discovered that OCT4,
SOX2, and KLF4 function as ‘‘pioneer factors’’ by facili-
tating chromatin access to target genes. Moreover, his
laboratory identiﬁed broad genomic regions, marked by
H3K9 methylation, that remain refractory to transcription
factor binding during the initial phase of reprogramming
but are ultimately bound in the minority of cells that
become reprogrammed. These genomic regions include a
number of core pluripotency genes such as SOX2 and
ESRRB, and their initial lack of activation thus appears to
provide a bottleneck for efﬁcient and fast reprogramming.
Ludovic Vallier (Cambridge Stem Cell Institute, UK)
compared human iPSCs derived from different individuals
and cell types using distinct reprogramming methods to
assess the degree of variation introduced by cell of origin,
genetic background, and iPSC derivation strategy. Two
important conclusions emerged from this analysis. First,
interindividual genetic differences had by far the strongest
impact on differentiation potential whereas cell type of
origin and reprogramming method contributed much
less. Second, variability in differentiation potential can be
abrogated by deriving endodermal progenitor cell lines
priortoderivationofamoreterminallydifferentiated state.
The latter point was also made by Oliver Bruestle (Univer-
sity of Bonn Medical Center, Germany), who emphasized
the advantage of ﬁrst deriving neural progenitor cell lines
from iPSCs before coaxing them into neuronal or glial
cell fates for comparative studies. Vallier also presented
ongoing efforts by the UK-based initiative HipSci (http://
www.hipsci.org) to derive large numbers ( 500) of control
and patient-derived iPSC lines with the goal to detect
the impact of genetic variation on disease and cellular
phenotype.
George Daley’s laboratory (Boston Children’s Hospital,
USA) is taking steps to derive hematopoietic stem cells
(HSCs) from pluripotent and other cellular sources. He
summarized recent work on transcriptional analyses of
different stages of HSC development, which identiﬁed
NOTCH signaling as a limiting component in culture-
derived HSC-like cells (McKinney-Freeman et al., 2012).
Given that blood cells are exposed to certain shear forces
in vivo, Daley’s laboratory utilized microﬂuidics technol-
ogy to mimic the effect of blood ﬂow on in vitro-derived
cells. This strategy indeed activated Notch signaling and
enhanced formation of more deﬁnitive hematopoietic
cell fates. A major limitation in the HSC ﬁeld is that HSC-
like cells derived from pluripotent cells fail to engraft
long term upon transplantation. In an attempt to resolve
this shortcoming, Daley’s group has devised a screening
approach to identify transcription factors that can revert
hematopoietic progenitors into authentic, transplantable
HSCs (Doulatov et al., 2013). Overexpression of ERG,
HOXA9, and RORA in short-term progenitors was indeed
sufﬁcient to produce cells that engrafted for several weeks,
reconstitutedthemyeloidandlymphoidlineages,andgave
rise to red blood cells expressing adult b-globin.
Benoit Bruneau (Gladstone Institute of Cardiovascular
Disease, USA) summarized work on the epigenetic and
transcriptional analyses of pluripotent cells undergoing
step-wise differentiation into cardiomyocytes via meso-
dermal and cardiac progenitor intermediates (Wamstad
et al., 2012). This analysis provided a chromatin landscape
of enhancers that become sequentially activated and
predict binding of other regulatory transcription factors
based on motif analysis. In follow-up experiments,
Bruneau’s laboratory discovered that the SWI/SNF compo-
nent BRG1 is responsible for establishing these enhancers.
BRG1 was shown to co-occupy H3K27-acetylated meso-
derm enhancers, and its genetic deletion at the mesoderm
progenitor stage abrogated the formation of cardiomyo-
cytes due to inefﬁcient activation of mesodermal genes
and ectopic expression of other lineage markers. Interest-
ingly, BRG1’s role in suppressing alternative cell fates
during cardiac mesoderm induction was proposed to
involve modulation of Polycomb activity, but not binding,
at target genes.
Reprogramming and Transdifferentiation
The reprogramming of somatic cells into iPSCs is notori-
ously inefﬁcient and the underlying mechanisms are
incompletely understood. Jacob Hanna (Weizmann
Institute,Israel)presentedintriguingdata,whichsuggested
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SOX2, KLF4, and c-MYC normally fail to efﬁciently repro-
gram somatic cells because of their aberrant recruitment
oftherepressormoleculeMBD3totargetgenes.Thismech-
anism was suggested to prevent the ability of most cells
to become iPSCs. Consistent with this model, depletion
of Mbd3 from mouse or human ﬁbroblasts increased the
efﬁciencyofiPSCinductionfromafewpercentuptonearly
100% (Rais et al., 2013). Hanna’s data further documented
that all Mbd3-depleted cells undergo reprogramming into
iPSCswithin8daysinanapparentlydeterministicmanner.
Similarly, loss of Mbd3 enhanced the normally inefﬁcient
‘‘spontaneous’’ reprogramming of unipotent primordial
germ cells into pluripotent embryonic germ cells and that
of epiblast stem cells into ESCs from 5%–10% up to 90%–
100%.
The 2013 recipient of the ISSCR-University of Pittsburgh
Outstanding Young Investigator Award (Figure 2) Marius
Wernig (Stanford University, USA) presented a road map
of his laboratory’s work reviewing the strategies they ex-
ploited to transdifferentiate murine and human ﬁbroblasts
into functional neurons. Wernig had previously shown
that a combination of three transcriptional factors was
sufﬁcient to convert ﬁbroblasts into neurons. In recent
experiments, Wernig has discovered that one of the trans-
differentiation factors, ASCL1, functions as a pioneer
factor that can bind to nucleosomal DNA at its cognate
targets in the ﬁbroblast chromatin (Wapinski et al.,
2013). Moreover, it recruits BRN2, another reprogramming
factor, to many of its target sites. Genome-wide chromatin
analysis revealed that ASCL1 target sites are enriched in a
novel trivalent histone conﬁguration consisting of H3K4
monomethylation, H3K27 acetylation, and H3K9 trime-
thylation, which canpredict the permissivenessofinduced
neuron reprogramming among different cell types.
Disease Modeling and Cell Therapy
After great coverage on the basic biology of stem cell regu-
lation and potency, the focus of the meeting transitioned
to questions addressing the utilization of stem cells for
modeling and treating disease.
Lawrence Goldstein (University of California, San Diego,
USA) presented his laboratory’s progress in deciphering the
mechanisms of Alzheimer’s disease using iPSCs as a model.
A hallmark of Alzheimer’s disease is the formation of
plaques containing amyloid-beta protein as their major
constituent. Previous work from the laboratory has shown
that patient iPSC-derived neurons recapitulate phenotypic
aspects of the disease in vitro, such as increased levels
of amyloid-beta and hyperphosphorylated TAU protein
(Israel et al., 2012). Based on this in vitro system, Gold-
stein’s laboratory has uncovered one mechanism by which
anAlzheimer’sdiseaseriskallele,SORL1,affectsanincrease
in amyeloid-beta levels and has developed an assay that al-
lows identiﬁcation of protective alleles.
Bruestle also summarized his laboratory’s efforts in
modeling Alzheimer’s disease and polyglutamine disorders
using pluripotent stem cells (PSCs). The team expressed a
pseudo-hyperphosphorylated variant of the TAU protein
in PSC-derived neurons. They found that this leads to
defects in axonal transport of mitochondria resulting in
axonal pathology and a slow neurodegeneration when
the cells were cultured under non-redox-protected condi-
tions (Mertens et al., 2013). In another line of experiments,
the group demonstrated that neurons derived from Alz-
heimer’s disease iPSCs can be used to assess the efﬁcacy of
pharmaceutical compounds modulating amyloid precur-
sor protein processing. As a prelude to exploiting direct
neuronal conversion for disease modeling, they used small
moleculestoboosthumanﬁbroblast-to-neuronconversion
to yields exceeding 150%.
KristinBaldwin(ScrippsResearchInstitute,USA)isinves-
tigating the genetic integrity of adult postmitotic neurons
through reprogramming by somatic cell nuclear transfer
(SCNT). Her laboratory derived ESC lines produced from
seven active adult postmitotic neurons from the olfactory
bulb (mitral and tufted neurons) through SCNT in mouse.
Three of the resultant nuclear transfer (NT)-ESC lines gave
rise to entirely stem cell-derived mice using tetraploid
embryocomplementation,whereas three other testedlines
did not, documenting that the genome of at least some of
these neurons is genetically fully pluripotent. Extensive
genome-wide sequencing analyses of three NT-ESC lines
derived from the same 4.5-month-old donor animal (one
line was capable of producing viable mice and the other
Figure 2. ISSCR Outstanding Young Investigator Award
Winner Marius Wernig (right) with Shinya Yamanaka, ISSCR
President (2012-2013).
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genomic mutation, including rare and complex structural
variants that appeared to be speciﬁc to the individual
neuron (not expressed in any other tissues) and a consider-
able number of point mutations and ‘‘indels.’’ Each neuron
carried a unique set of mutations, and no shared mutations
were observed. Together, this suggests that many of these
mutations may have occurred in the nondividing postmi-
totic stage of each neuron. However, these aberrations did
not correlate with the cells’ ability to generate mice. The
functional consequence of these abnormalities remains
to be elucidated.
Shoukhrat Mitalipov’s laboratory (Oregon Health and
Science University, USA) is studying nuclear transfer in
primates, recently using this technique to replace one ani-
mal’s defective mitochondrial DNA in an oocyte with that
from a nonaffected animal. In further studies, Mitalipov
succeeded in human SCNTand in deriving ﬁrst, SCNT blas-
tocysts and then human NT-ESCs, which remained one of
the major barriers in the cloning ﬁeld (Tachibana et al.,
2013). Optimization of oocyte/donor cell synchronization
and subsequent activation were key for successful NT-ESC
derivation. This allowed him to compare transcriptional,
epigenentic, and genomic differences between human
pluripotent stem cell lines derived by SCNT, iPSC technol-
ogy, or in vitro fertilization. A preliminary analysis found
differences between the approaches at the level of genetic
stability. For example, iPSCs appeared to have a 3-fold
increase in the number of copy-number variations com-
pared with NT-ESC lines. Global methylation analysis
suggested that NT-ESCs more closely resemble genuine
in vitro fertilization-derived ESCs than iPSCs.
Alessandra Bifﬁ (Ospedale San Raffaele, Italy) discussed
her recent work on metachromatic leukodystrophy, a
demyelinating lysosomal storage disorder caused by muta-
tion in the arylsulfatase A (ARSA) gene, which is normally
produced by microglia. HSCs from presymptomatic pa-
tients were infected with third generation ARSA-encoding
lentivirus. After HSC correction, patients showed evidence
of therapeutic beneﬁt for many months beyond the pre-
dicted disease onset (Bifﬁ et al., 2013). Moreover, vector
integration into HSCs revealed stable engraftment, sus-
tained polyclonal contribution, and normal behavior.
These data provide compelling evidence for the successful
treatment of human malignancies with genetically engi-
neered stem cells.
Charles Murry (University of Washington, USA) dis-
cussed his recent work using human ESCs to improve
cardiac recovery after infarction in nonhuman primates.
Cardiomyocytes derived from human ESCs were injected
into the left ventricle of nonhuman primates that had
undergone an experimentally induced infarct. The human
cardiomyocytes repopulated approximately 40% of the
infarct (2% of the left ventricle) and led to a signiﬁcant
improvement of cardiac repair based on morphological
and functional indicators. These ﬁndings provide proof-
of-principle that human ESCs can be used to augment
repair of terminally differentiated tissue in nonhuman
primates.
Tissue-speciﬁc Stem Cells
Many excellent talks at ISSCR 2013 focused on tissue-
speciﬁc adult stem cells in the skin, blood, brain, and mus-
cle. Elaine Fuchs (Rockefeller University, USA) presented
the Anne McLaren Memorial Lecture and provided an
overview of skin biology, discussing epidermal stem cells
in vitro, skin grafts, squamous carcinoma, and regulation
of hair follicle stem cells. Over the past few years, the Fuchs
laboratory has uncovered a network of epigenetic and
genetic regulators of stem cell fate. More recently, they
have investigated apoptosis as a homeostatic regulator of
stem cell number. Fuchs presented a recent collaboration
with Hermann Steller’s laboratory using a conditional
knockout of ARTS (inhibitor of the antiapoptotic factor
XIAP) in hair follicle stem cells (Fuchs et al., 2013). Loss
of this apoptosis inhibitor led to increased survival and a
2-fold increase in the number of stem cells. Moreover,
wound repair and hair regrowth was accelerated after
ARTS deletion. Importantly, when XIAP was deleted in
the ARTS mutant background, stem cell number and
woundresponsewasrestoredtonormal.Thisdemonstrates
the balance between anti- and proapoptotic regulators in
achieving stem cell homeostasis.
Next, Fuchs discussed the signaling transduction be-
tween extracellular morphogens andthe microtubule cyto-
skeleton, necessary for cell polarity of proliferating stem
cells in the hair follicle. It is known that WNT is a potent
regulatorofpolarityandcellfateinstemcellsfromdifferent
niches. Fuchs demonstrated that a downstream target of
the WNT morphogen, GSK3b, is a substrate for the micro-
tubule cytoskeletal protein ACF7, thus demonstrating a
mechanistic link between morphogens and cell polarity
effectors that controls stem cell fate (Wu et al., 2011).
Paul Frenette (Albert Einstein College of Medicine, USA)
and Charles Lin (Massachusetts General Hospital, USA)
discussed their efforts to track stem cells and deﬁne their
niches. Frenette used Nestin-GFP reporter mice to distin-
guish two distinct vascular niches, demonstrating arteri-
olar stromal niche cells as NESTIN
hi and sinusoidal stromal
niche cells as NESTIN
low (Kunisaki et al., 2013). During
normal homeostasis, quiescent HSCs, in contrast to active
HSCs, were more often localized to NESTIN
hi arterioles.
Various perturbations were used to drive HSCs into cycle
and led to a redistribution of active HSCs away from the
arterioles. Those HSCs that remained quiescent remained
in close proximity to the arterioles. Using a computational
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HSCs to arterioles was nonrandom, which led him to spec-
ulate that there is a protective zone in the niche that
actively maintains HSC dormancy. Lin added anextra layer
of information on niche regulation of HSCs using live
imaging in vivo. He addressed the apparent contradiction
that stem cells are thought to reside in a hypoxic niche,
yetaresurroundedbyoxygen-carryingbloodvessels.Using
sophisticated sensor and imaging systems, the absolute
local oxygen concentration in distinct niches within the
bone (using Nestin-GFP reporter mice) could be measured
in addition to imaging blood ﬂow rate. Lin demonstrated
that due to the high vascularity of the bone, the majority
( 90%) of bone marrow cells are in close proximity
(<25 mm) to blood vessels. However, oxygen concentration
drops off dramatically as blood vessels enter the bone
marrow space, perhaps due to a high oxygen consumption
of bone marrow cells. Interestingly, the perisinusoidal
regions have a lower oxygen concentration, while the
high NESTIN-expressing vessels, thought to mark the
stemcellniche,haverelativelyhighoxygenconcentration.
After chemotherapy or radiation treatment, transplanted
HSCsdidnotseekoutareasoflowestoxygenconcentration
as preferential sites for homing.
Fiona Doetsch (Columbia University, USA) presented
work on adult neural stem cells (NSCs) in the subventricu-
lar zone (SVZ). Doetsch has identiﬁed a series of marker
combinations that can be used to distinguish between
quiescent and activated NSCs. Based on the expression of
these markers, it was shown that activated NSCs are prefer-
entially located next to blood vessels, interestingly at sites
that lack astrocyte end-foot coverage, suggesting that
both direct contact-mediated and diffusible signals from
the vasculature are important in this niche. In addition,
signals from the blood directly access the SVZ. To better
understand the differences between the vasculature of the
SVZ versus a nonneurogenic region, the cortex, Doetsch
hasestablishedcoculturesofNSCswithpericytes,endothe-
lial cells, or cerebrospinal ﬂuid-enriched media. This work
isbeginningtounravelthespeciﬁcgrowthfactorsandtheir
cellular sources that differentially target quiescent and
activated NSCs.
Luis Fuentealba (University of California, San Francisco,
USA; Alvarez-Buylla laboratory) presented his recent work
using a retrovirus barcode library and other lineage-tracing
methods to identify the embryonic origin of adult SVZ
NSCs. His work demonstrates that precursors of adult
NSCs are separate from the other embryonic progenitors
at E13.5–E15.5 and that a common progenitor may be
present at E12.5. In addition, cycling cells at E15.5 form a
large fraction of the adult NSC pool. This elegant work
demonstrates the ability to track early forming adult cells
in the embryo.
Turning to the skeletal muscle, Helen Blau (Stanford Uni-
versitySchool ofMedicine, USA) describeda bioengineered
niche developed in her laboratory a few years ago and the
group’s continued work to identify strategies that augment
stem cell function during aging (Lutolf and Blau, 2009).
Blau showed that aged muscle stem cells (MuSCs) have a
signiﬁcant, intrinsic defect in self-renewal capacity and
regenerative function compared to young MuSCs, when
transplanted into irradiated injured muscles. Analysis of
signaling cascades illustrated that elevated p38 mitogen-
activated protein kinase (MAPK) activity was driving the
loss of self-renewal in MuSCs. In combination with the
bioengineered niche, an inhibitor of p38 MAPK activity
increased stem cell engraftment, self-renewal, and regene-
ration through serial rounds of transplantation, thus
demonstrating a rejuvenation of the population of stem
cells. Importantly, the contractile force of the new muscle
in transplant recipients of aged MuSCs was also greatly
improved when donor cells were treated with the p38
MAPK inhibitor. These data highlight the synergistic inter-
action of biophysical and biochemical cues in rejuvenating
and restoring the function of a MuSC population lost
during aging.
Robert Signer (University of Texas Southwestern Medical
Center; Sean Morrison’s laboratory) presented a novel
approach to study the rate of protein synthesis of HSCs
and their progeny in vivo. Previous methods to calculate
global protein synthesis rates have relied on population-
based averaging in vitro. Using a FACS-based readout,
Signer reported that HSCs synthesize nascent proteins at
a slower rate than lineage-restricted progenitors, irrespec-
tive of whether the HSCs are quiescent or undergoing
self-renewing divisions. Moreover, genetic strategies that
increase or decrease protein synthesis impaired HSC
function. This approach raises the possibility that the
longevity of some long-lived cells depends upon a low
rate of protein synthesis. This will undoubtedly be infor-
mative for the analysis of protein synthesis in other stem
cell compartments.
This year’s annual meeting concluded with a keynote
lecture delivered by Eric Lander (Broad Institute of MIT
and Harvard University, USA). With his fascinating and
energetic look at some of the secrets that have been
uncovered about the human genome, Lander addressed
several issues that have direct implications on research
using stem cells, particularly with regard to the causes of
a variety of human diseases. Through the systematic map-
ping of genetic variants, more than 2000 loci have been
implicated in more than 250 common diseases including
age-related macular degeneration and cancer. The lessons
learned and shared by Lander and all of the presenters
this year in Boston will continue to shape the fast-paced
ﬁeld of stem cell research, the effects of which will be
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th Annual Meeting in Vancou-
ver in 2014.
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